Departments of Neurology, Cangzhou Central Hospital, Cangzhou 061000, China.
Neurosurgery, Cangzhou Central Hospital, Cangzhou 061000, China
eNeuro. 2024 Oct 1;11(10). doi: 10.1523/ENEURO.0239-24.2024. Print 2024 Oct.
This study aims to explore the correlation of serum thyroid hormone levels to cognitive impairments in Parkinson's disease (PD) patients. In this retrospective study, 106 Chinese patients without cognitive impairments and 94 patients with cognitive impairments, including 55 with mild cognitive impairment (PD-MCI) and 39 with PD dementia (PDD), were analyzed. Clinical data regarding the PD assessments, including disease duration, Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 scores, and Hoehn and Yahr (H-Y) staging, were analyzed. Cognitive functions were evaluated using the Montreal Cognitive Assessment score. Serum levels of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3), were measured using ELISA. Significantly altered H-Y staging, disease duration, and UPDRS Part 3 scores were observed in PD patients with cognitive impairment compared with those without. Serum levels of FT3 were significantly decreased, while FT4 and TSH levels were significantly elevated in PD patients with cognitive impairment compared with those without. Combined detection of TSH, FT3, and FT4 showed value in distinguishing PD patients with and without cognitive impairment. Furthermore, a comparison of serum levels between PD-MCI and PDD patients revealed significant association between thyroid hormone levels and the degree of cognitive impairment in PD patients. Our findings suggest a relationship between changes in serum thyroid hormone levels and cognitive impairments in PD patients. Thyroid hormone levels, particularly FT3, may serve as potential markers for cognitive dysfunction in PD.
本研究旨在探讨帕金森病（PD）患者血清甲状腺激素水平与认知障碍的相关性。在这项回顾性研究中，分析了 106 例无认知障碍的中国患者和 94 例有认知障碍的患者，包括 55 例轻度认知障碍（PD-MCI）和 39 例帕金森病痴呆（PDD）。分析了与 PD 评估相关的临床数据，包括疾病持续时间、统一帕金森病评定量表（UPDRS）第 3 部分评分和 Hoehn 和 Yahr（H-Y）分期。使用蒙特利尔认知评估量表评估认知功能。使用 ELISA 测量血清促甲状腺激素（TSH）、游离甲状腺素（FT4）和游离三碘甲状腺原氨酸（FT3）水平。与无认知障碍的 PD 患者相比，有认知障碍的 PD 患者的 H-Y 分期、疾病持续时间和 UPDRS 第 3 部分评分明显改变。与无认知障碍的 PD 患者相比，有认知障碍的 PD 患者的 FT3 水平显著降低，FT4 和 TSH 水平显著升高。TSH、FT3 和 FT4 的联合检测对区分有和无认知障碍的 PD 患者具有价值。此外，对 PD-MCI 和 PDD 患者的血清水平进行比较，发现甲状腺激素水平与 PD 患者认知障碍的严重程度之间存在显著关联。我们的研究结果表明，PD 患者血清甲状腺激素水平的变化与认知障碍之间存在关系。甲状腺激素水平，特别是 FT3，可能是 PD 患者认知功能障碍的潜在标志物。
